Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
Authors:
- Jean-Claude AnsquerJAJean-Claude Ansquer
- Christelle FoucherCFChristelle Foucher
- Stephanie RattierSRStephanie Rattier
- Marja-Riitta TaskinenMTMarja-Riitta Taskinen
- George SteinerGSGeorge Steiner
- DAIS InvestigatorsDIDAIS Investigators
- 1 March 2005
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 45 (3) , 485-493
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Treatment of the Patient With Diabetes Mellitus and Risk of NephropathyArchives of internal medicine (1960), 2004
- Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular DiseaseJournal of the American Society of Nephrology, 2003
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised studyThe Lancet, 2001
- Effect of lipid reduction on the progression of renal disease: A meta-analysisKidney International, 2001
- Laboratory standardization of a large international clinical trial: the DAIS experienceClinical Biochemistry, 2000
- Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational studyBMJ, 1997
- The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health OrganizationDiabetologia, 1996
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesNew England Journal of Medicine, 1984
- LIPID NEPHROTOXICITY IN CHRONIC PROGRESSIVE GLOMERULAR AND TUBULO-INTERSTITIAL DISEASEThe Lancet, 1982